Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Datopotamab Deruxtecan Metastatic Prostate Carcinoma	AstraZeneca	P2	CCC (48)
PREDNISONE TABLETS Endometrial Carcinoma	AstraZeneca	P2	CCC (48)
PREDNISONE TABLETS Gastric Cancer	AstraZeneca	P2	CCC (48)
Rilvegostomig Metastatic Prostate Carcinoma	AstraZeneca	P2	CCC (48)
Volrustomig Endometrial Carcinoma	AstraZeneca	P2	CCC (48)
Volrustomig Gastric Cancer	AstraZeneca	P2	CCC (48)
Volrustomig Hepatocellular Carcinoma	AstraZeneca	P2	CCC (48)
Volrustomig Metastatic Prostate Carcinoma	AstraZeneca	P2	CCC (48)
Camizestrant Healthy Volunteers	AstraZeneca	P1	CCC (48)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Advanced/Recurrent Ovarian Cancer	AstraZeneca	P1/2	CCC (48)
AZD2287 Metastatic Prostate Carcinoma	AstraZeneca	P1/2	CCC (48)
azd3470 Advanced Solid Tumors That Are MTAP Deficient	AstraZeneca	P1/2	CCC (48)
azd3470 Angioimmunoblastic T-Cell Lymphoma	AstraZeneca	P1/2	CCC (48)
azd3470 Anaplastic Large Cell Lymphoma	AstraZeneca	P1/2	CCC (48)
azd3470 Peripheral T-Cell Lymphoma, Not Otherwise Specified	AstraZeneca	P1/2	CCC (48)
azd3632 Acute Myeloid Leukemia	AstraZeneca	P1/2	CCC (48)
azd4360 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P1/2	CCC (48)
azd4512 B-Cell Acute Lymphoblastic Leukemia	AstraZeneca	P1/2	CCC (48)
azd5305 Additional Indications Below for Module 4 and 5	AstraZeneca	P1/2	CCC (48)
azd5305 Biliary Tract Cancer	AstraZeneca	P1/2	CCC (48)
azd5863 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P1/2	CCC (48)
azd6750 Skin Squamous Cell Carcinoma	AstraZeneca	P1/2	CCC (48)
azd8421 Estrogen-Receptor Positive Breast Cancer	AstraZeneca	P1/2	CCC (48)
azd8853 Urinary Bladder Neoplasm	AstraZeneca	P1/2	CCC (48)
Camizestrant Additional Indications Below for Module 4 and 5	AstraZeneca	P1/2	CCC (48)

Showing 176 to 200 of 502 assets

PreviousPage 8 of 21Next